10 September - 13 September 2023

SCI / RSC 22nd Medicinal Chemistry Symposium

Organised by:

SCI’s Fine Chemicals Group and RSC’s Biological and Medicinal Chemistry Sector 

Churchill College, Cambridge, UK

Register your interest
The organisers invite you to the 22nd SCI-RSC Medicinal Chemistry symposium, Europe’s premier biennial Medicinal Chemistry event, focusing on first disclosures and new strategies in Medicinal Chemistry.
Call for posters

For further information on abstract deadlines, please contact conferences@soci.org.

Exhibition and Sponsorship

Churchill College is an ideal venue for exhibitors. All refreshments, the exhibition and posters will be situated in a single area, ensuring excellent access to delegates throughout the meeting.

The exhibition will run alongside the conference during refreshment breaks and poster sessions. Those who wish to exhibit are encouraged to book early to avoid disappointment. Exhibition stands will be available to book via the registration page when registration opens, and the rate will include two stand staff and daytime refreshments.  

For further details, please contact conferences@soci.org

Confirmed Talks

The discovery of sebetralstat, an oral, small molecule oral plasma kallikrein inhibitor to treat attacks of hereditary angioedema

Rebecca Davie, KalVista

Discovery of reversible highly potent and selective MAGL inhibitors 

Uwe Grether, Roche

Discovery and first-time disclosure of NT-0796, a clinical phase NLRP3 inflammasome inhibitor for inflammation

David Harrison, NodThera

LMW inhibitors of IL-1β, from fragment hits to cellular PoC

Konstanze Hurth, Novartis Institutes for BioMedica

Discovery of LAS202051, a potent Acetyl-CoA Carboxylase (ACC) inhibitor for the topical treatment of acne

Jordi Bach Taña, Almirall

Discovery of a novel class of brain penetrant inhibitors of KRAS G12C

Jason Kettle, AstraZeneca

Fadaltran, a Selective Antagonist for the Peripheral AR alpha 2c Receptors: A New Option for the Treatment of Diabetic Foot Ulcers?

Carsten Schmeck, Bayer

Fragment-based drug discovery approaches to the development of protein-protein interaction inhibitors

Dr John Skidmore, The ALBORADA Drug Discovery Institute, University of Cambridge

Plasmepsin X inhibitors with in vivo antimalarial activity

Teresa de Haro Garcia, UCB

Discovery of VX-147 as a Targeted Therapy for APOL1‑mediated Kidney Disease’

Les Dakin, Vertex

Lessons Learnt building the GSK pan-BET bromodomain portfolio

Phil Humphreys, GSK

Gamma Secretase Modulator for the treatment of Alzheimer's Disease

Rosa Maria Rodriguez Sarmiento, Hoffman La Roche

SAGE-718, a compound in phase II for a variety of CNS indications. (NMDAR PAM)

Matthew Hill

Further details will be available in due course.
The programme will be announced in due course. 
Venue and Contact

Churchill College

Storey's Way 

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

The fees will be announced in due course. 

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process/Deadlines

Booking terms and conditions


Organising Committee
Nadia Ahmad, Charles River
Mark Healy, Novartis
Joanne Pinder , Vertex 
Jamie Scott, AstraZeneca
John Cumming, Roche
Gordon Saxty, NS-MC Consulting 
Chris Swain, Cambridge MedChem Consulting
Andrew Williams, Chairman of the RSC BMCS